Skip to content

BioSig Technologies, Inc. STEX Loss On Warrant Settlement

Loss On Warrant Settlement at other companies

Cinemark Holdings logo
Cinemark HoldingsCNK
$9.83M
Cinemark Holdings logo
Cinemark HoldingsCNK
$0
BillionToOne, Inc.
 logo
BillionToOne, Inc. BLLN
$211.25K
Palladyne AI Corp. logo
Palladyne AI Corp.PDYN
-$1.05M-104%
NovaGold Resources logo
NovaGold ResourcesNG
$0-100%
AMMO, Inc. logo
AMMO, Inc.POWW
$7.09M

Segments

By segment

See full
Corporate$8.05M

Other financials

Income statement

See full
Revenue$13.0K+8.3%
Gross profit$12.0K-88.9%
Operating income-$35.7M-1,098%
Net income-$46.7M-1,560%
EPS (diluted)-$0.27-92.9%

Balance sheet

See full
Cash & equivalents$6.9M+84.0%
Total debt$15.0K-94.7%
Total equity$159.0M+6,003%
Total assets$173.3M+3,823%

Cash flow

See full
Operating cash flow-$10.2M-813%
CapEx$4.0K-93.1%
Free cash flow-$2.9M+29.4%

Valuation

See full
Market cap$88.66M-61.8%
P/S2,216.6×-5,967×

Profitability

See full
Gross margin80.1%+25.2pp
Operating margin-32,155%-14,261pp
Net margin-25,825%-11,789pp
FCF margin-97,216.7%-106,293pp

Returns & leverage

See full
Return on equity-627.1%
Debt / equity
Current ratio13.9×+11.5×

Where this comes from

Reported directly by BioSig Technologies, Inc. in its filing.

Tagged under the XBRL concept STEX:LossOnWarrantSettlement.

The official record: BioSig Technologies, Inc.’s 10-K, filed March 31, 2026, on SEC EDGAR. View the filing →

Ask your AI about BioSig Technologies, Inc.'s loss on warrant settlement.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is BioSig Technologies, Inc.'s loss on warrant settlement?
BioSig Technologies, Inc. (STEX) reported loss on warrant settlement of $2.01M in Q4 2025.
What does loss on warrant settlement mean?
This metric captures the financial loss incurred when the company settles outstanding warrants, often due to changes in the underlying stock price or the terms of the warrant agreement. It represents a non-operating expense that can significantly impact net income without reflecting core operational performance. Investors analyze this to understand the dilution risk and the cost of capital associated with equity-linked financing instruments.